Seeking Alpha readers, please enjoy a Complimentary Trial to our Premium content: http://wallstcheatsheet.com/premium/
Only days after the S&P 500 crashed to the depths of hell at 666, the Hoffman brothers launched Wall St. Cheat Sheet: one of the fastest growing financial media sites on the web. Like a samurai, our mission is to cut through the bull and bear sh** with extraordinary insights, a fresh voice, and razor-sharp wit. We provide the highest quality education and information for active investors and financial professionals. We are official contributors to Yahoo Finance, CNNMoney, the Chicago Mercantile Exchange, Business Insider, The Huffington Post, Minyanville, SeekingAlpha, and Zero Hedge. Our work has been cited in top finance and trading outlets such as The Wall Street Journal, MarketWatch, Financial Times, The Big Picture, Real Clear Markets, The Atlantic, Business Insider, The Huffington Post, Infectious Greed, DealBreaker, CBS MoneyWatch, Kiplinger, Investment Postcards, ZeroHedge, Business Pundit, TraderFeed, The Kirk Report, AbnormalReturns, and more.
For the Premium Complimentary Trial: http://wallstcheatsheet.com/premium/
Damien Hoffman, Esq. decided to launch a financial website and exclusive subscription-based newsletter after achieving a 63% return versus a -48% return for the S&P over a nearly two year time frame as a co-founder of popular stock blog SmartGuyStocks (member of the Forbes Business and Finance Blog Network, and certified by Seeking Alpha). Mr Hoffman is currently Editor-in-Chief of Wall St. Cheat Sheet and trades full-time. After graduating early with honors from Duke University, he raised private equity with friends during the late Nineties to launch a successful start-up. Mr. Hoffman went on to work for boutique sports investment bank Inner Circle LLP where he worked on the sale of the NBA franchise New Jersey Nets to Brooklyn real estate development firm Forest City Ratner Companies (NYSE: FCE-A). Mr. Hoffman also graduated with honors from the University of Miami School of Law as a Dean’s Merit Scholar. He clerked at the Florida Supreme Court for the Honorable Justice Kenneth Bell and Central Staff. In 2006 at Harvard Law School he gave a guest lecture entitled, “Business and Law in the New Independent Music Industry.”
Derek Hoffman joined efforts with his brother to launch Wall St. Cheat Sheet after a decade of investing experience and outperforming the S&P 500 over the past 5 years. Mr. Hoffman is currently the CEO of Wall St. Cheat Sheet and trades full-time. He is a regular contributor to CNNMoney. His long-term investments and short-term trades have yielded extraordinarily successful results: double digit annual returns. Mr. Hoffman has handled media investment and tactical strategy planning for Procter & Gamble and Gillette’s national asset portfolio. He has also worked in private wealth management for Morgan Stanley. Mr. Hoffman graduated early from the University of Michigan’s world class economics department.
For the Premium Complimentary Trial: http://wallstcheatsheet.com/premium/
Mark Mansfield has 3 years of experience in brokerage with Fidelity Investments. Mark has passed two levels of the Chartered Financial Analyst exam, interned as a fixed income analyst for Principal Global Investors, and has an MBA-Finance from Indiana University.
Brandon Matthews (pseudonym) is the founder of SatwavesPro.com, which was borne of his desire to help retail investors after witnessing the continually changing ways that Wall Street can cheat them. Brandon has worked for Monroe Parker Investment Bankers, Morgan Stanley Dean Witter, American Express Financial Advisors, David Lerner Associates and a private equity firm as a stock and bond broker.
Brandon held Series 7, 63, 65, 31, Life, Health, Variable Annuity and Variable Life Securities and Insurance Licenses and was a registered investment advisor in New York, New Jersey, Florida and Connecticut.
Brandon combines an expertise in point & figure technical analysis with basic fundamental research to provide actionable recommendations.
Brandon is a Gold Level Contributor to Seeking Alpha and a top ranked author, had a significant role as an expert in the documentary Stock Shock, and is working on his first book.
Sheff can be followed at twitter.com/SheffStation. He is an investor & trader of big board, small cap, and biotech stocks. He uses fundamental analysis and extensive DD (due diligence) to trade. Over the years, he has learned a great deal about how the FDA works and what they look for when considering a drug for approval. His success record in stock picking and many yrs in the biotech & pharmaceutical industry has helped him in his analysis of biotech & pharma stocks. His goal is to find undervalued companies and help the individual investor by discussing clinical data that could be relevant in how the FDA will make a decision for a drug or clinical data.
Do your own due diligence and never buy a stock based on what Sheff discusses or says.
Sheff is is not a licensed broker or financial advisor of any kind nor is he qualified to act as an investment advisor. His articles are written for discussion purposes only. None of the information written about by Sheff is to be construed as financial or investment advice. The information shared is not to be construed as an offer to buy or sell any security. Sheff works diligently to avoid misstatements of fact, but advises all investors to consult a licensed profession prior to making an investment in any stock he discusses. The information on this site is gathered from sources available to the public
Sheff's hobbies are reading, family, and helping people. I enjoy the work I do as a Chemo Specialist in many cancer centers and the volunteer work as a member with a Cancer Organization where I raise money for awareness & other programs vital for children with different forms of cancer.
I'm Ruthanne Williams Roussel, a reformed sell-side analyst who has covered the obesity space for several years. Unlike anyone else I've met who covers these companies for the big banks, I am among the target market for most of these products, which allows me to bring a consumer's perspective. In a past life, before the Asian/Russian currency crisis of 1998, I was an emerging markets specialist. Since then, I've been drawn to the closest things I can find: special situations and small-cap stocks.
M.E. Garza is one of the founders of the biotech and healthcare sector news portal BioMedReports.com. He believes in getting the news from credible sources on the street and often reaches out to CEOs and newsmakers directly for interviews and discussions about their companies. Since he began publishing in 2008, Garza has built a reputation as a writer and reporter who can move markets. His track record for accurately reporting rumors and alerting readers about developments in the biotech/healthcare sector is unmatched during that time.
Philstockworld.com is the fastest growing stock and option newsletter on the Web. "High Finance for Real People - Fun and Profits" is our motto and our Basic and Premium Chat Sessions offer readers a chance to speak to Phil live during the trading day as well as authors like Optrader, Sabrient, Income Trader and Trend Trader - who send out Alerts during the market sessions and discuss trade ideas live with Members.
We even have a new low-cost "Trend Watcher" Membership that lets readers view our chat sessions without directly participating a great solution for people who want to test-drive the site and profit from our experience! Trend Watchers get to view all of our Chat Archives, weekly Webinars - as well as the amazing PSW Wiki, which gives you Phil's recent opinions and trade ideas as well as technical and fundamental analysis of hundreds of stocks that we follow.
Philip R. Davis is a founder of Phil's Stock World (www.philstockworld.com), a stock and options trading site that teaches the art of options trading to newcomers and devises advanced strategies for expert traders. Mr. Davis is a serial entrepreneur, having founded software company Accu-Title, a real estate title insurance software solution, and is also the President of the Delphi Consulting Corp., an M&A consulting firm that helps large and small companies obtain funding and close deals. He was also the founder of Accu-Search, a property data corporation that was sold to DataTrace in 2004 and Personality Plus, a precursor to eHarmony.com. Phil was a former editor of a UMass/Amherst humor magazine and it shows in his writing -- which is filled with colorful commentary along with very specific ideas on stock option purchases (Phil rarely holds actual stocks).
Visit: Phil's Stock World (www.philstockworld.com)
Market Folly is your go-to source for all the latest activity from prominent hedge funds. We're pleased to announce our brand new quarterly newsletter, Hedge Fund Wisdom. In it, you'll see what the hedge funds have been buying and selling. We track 25 of the most prominent managers in the game as well as provide in-depth equity analysis of the stocks they've been buying. Click the link below to see a free sample issue.
The author of Market Folly has experience at a long/short equity hedge fund, has been investing for a decade, and has degrees in Economics and Communications.
VFC is just a guy with an opinion. VFC's Stock House brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - the biotech, pharmaceutical and healthcare sectors. VFC's Stock House provides research, informational and opinion-based coverage of various companies and stocks in multiple sectors.
The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies. Do not Buy/Sell based solely on VFC's ideas or opinions.
The goal of VFC's Stock House is to 'call it like I see it' - while bringing new ideas, companies, and discussions to the eyes of investors and readers. This is supposed to be fun and new investors should not invest with the idea that this will 'pay the bills' or with the belief that a stock will just keep going up. DD is paramount, but so is sticking to pre-conceived entry and exit strategies and not letting emotional trading get in the way.
Goals must be realistic, if it sounds far fetched, then it probably is. Let the big boys eat the cake - the small investor is just trying to pick up some crumbs, and there's nothing wrong with that!
Douglas Cress is the former editor-in-chief of OneMedPlace (http://www.onemedplace.com/blog), a research firm focused on emerging healthcare and life sciences companies. He led conception and production of the company's publications, Med Tech Sentinel and Medical Technology Investment Digest from 2006 to 2008. Cress graduated with highest honors from Tufts University in 2004.
The enormous advancement in the biological sciences that is taking place has begun to change the traditional way of practicing medicine. Far-reaching biological products are being approved and news about breakthroughs are occupying the media headlines. However, selecting the biotechnology firms for investment requires not only an understanding of the company's finances, but also deep knowledge of the company's potential and the potential and scientific validity of it's products and technologies.
Our Mission is evaluating biotechnology companies, their products, their technologies, scientists, managements, as well as their finances. Our goal is to impart our readers with the knowledge and insight so that they may have a heightened understanding and appreciation for the biotechnology industry.
The Prohost Letter has been in circulation since 1992. Our readers are comprised of venture capital, fund managers, investors, medical professionals and individuals with one common interest, biotechnology.
Prohost Letter is posted in the members areas on the www.prohostbiotech.com. around 40 times a year. Articles are posted several times a week for subscribers in TODAY'S HIGHLIGHTS section and in News & Comments sector for all website visitors
With the tag line "Seeking Prosperity One Tiny Stock At A Time", the Microcap Speculator writes some of the sharpest insight we've seen on small and microcap stocks. The Microcap Speculator writes across a range of industries, and covers macro trends among micro stocks as well. Visit his site: The Microcap Speculator (http://microcapspeculator.net/)
We are NO LONGER and HAVE NOT BEEN contributing articles to SeekingAlpha since 2012. Visit us on our SmartKnowledgeU YouTube channel or at https://www.smartknowledgeu.com for up-to-date information.
After earning an undergraduate degree from the University of Pennsylvania and two master degrees (a Master in Public Policy and a Master in Business Administration) from the University of Texas at Austin, J.S. Kim started working within the Private Wealth Management division of one of the largest financial institutions in America. In 2005, dissatisfied with the ethics of the commercial investment industry and to be able to serve his clients in a manner consistent with his own commitment to integrity and honor, JS left the corporate world behind to launch his own company, SmartKnowledgeU™ (http://smartknowledgeu.com/), a fiercely independent investment research, consulting and education firm in 2006.
Mike Havrilla is a former pharmacist (retail and home infusion settings), biotech stock trader, and writer with experience that includes full-time online trading since 2009, working as a full-time pharmacist from 2004-2009, and writing for investors since 2007. Mike holds Doctor of Pharmacy (PharmD) and Bachelor of Science (Biology) degrees from the University of Pittsburgh and worked in the pharmaceutical industry for Wyeth prior to pharmacy school. He is also an avid runner and has completed over 20 marathons with a personal best time under three hours for the 26.2 mile race and under 80 minutes for the half marathon. Mike merged his former publishing business with BioRunUp.com / Mark Messier in October 2010, creating a new online biotech stock research and trading subscription service.